Novartis AG
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All NOT.DE news ›Novartis abandons Fabhalta trial in lupus nephritis
A failed phase 2 study has undermined Novartis' hopes of extending the approved indications for its oral complement inhibitor Fabhalta to include lupus nephritis. According to an update on the clinicaltrials.gov registry website, Novartis…
Novartis halts mid-stage trial for kidney drug, Fabhalta, in lupus nephritis
Novartis (NVS) ends a mid-stage trial for kidney drug Fabhalta (iptacopan) in lupus nephritis because of strategic considerations. Read more here. TBE/iStock Editorial via Getty Images Novartis (NVS) has terminated a mid-stage trial for…
Novartis in Society Integrated Report
Every day, we work to reimagine medicine to improve and extend people’s lives. Learn about us and our story. Visit our resource hub for information around clinical trials, our products and innovation pipeline. Learn about our commitment to…
The Novartis US Foundation
Every day, we work to reimagine medicine to improve and extend people’s lives. Learn about us and our story. Visit our resource hub for information around clinical trials, our products and innovation pipeline. Learn about our commitment to…
Novartis commitment to patients and caregivers
Every day, we work to reimagine medicine to improve and extend people’s lives. Learn about us and our story. Visit our resource hub for information around clinical trials, our products and innovation pipeline. Learn about our commitment to…
Novartis ends mid-stage Fabhalta trial targeting serious kidney condition
• The trial was evaluating whether the oral medication was safe and effective for treating lupus nephritis when added to standard medical care • Lupus nephritis is a severe inflammation of the kidneys caused by the autoimmune disease lupus…
Reimagining Healthcare in Challenging Times: Novartis in Society US Report for 2020
Every day, we work to reimagine medicine to improve and extend people’s lives. Learn about us and our story. Visit our resource hub for information around clinical trials, our products and innovation pipeline. Learn about our commitment to…
Novartis ends mid-stage Fabhalta trial in lupus nephritis for strategic reasons
Novartis has ended a mid-stage trial of Fabhalta for lupus nephritis, citing strategic considerations. The clinical-trial registry offered no further explanation and did not indicate whether safety or efficacy concerns played a role. · 6…
Vanda freezes Novartis-originated social anxiety program after late-stage disappointment
Vanda Pharmaceuticals is suspending the development of a social anxiety drug licensed from Novartis after the drug showed no significant benefit in a late-stage study. The investigational drug, called VQW-765, failed to significantly ease…
Royalty Pharma Announces Update on Novartis Phase 3 Topline Results for Pelacarsen
Royalty Pharma plc had announced an update on Novartis? Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied in patients with atherosclerotic... Royalty Pharma plc had announced an update on…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com26
-
tradingview.com5
-
biospace.com3
-
medicaldialogues.in3
-
news.bloomberglaw.com3
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 115 articles, not a forecast.